Protease inhibitors: a therapeutic breakthrough for the treatment of patients with human immunodeficiency virus

As one of the largest growing classes of antiretroviral drugs, protease inhibitors are promising agents for the management of patients infected with the human immuno deficiency virus (HIV). We reviewed the literature and compared efficacy, dosing, side effects, and drug-interaction profiles of the p...

Full description

Saved in:
Bibliographic Details
Published inClinical therapeutics Vol. 19; no. 2; pp. 187 - 214
Main Authors Lewis, James S., Terriff, Colleen M., Coulston, Daniel R., Garrison, Mark W.
Format Journal Article
LanguageEnglish
Published Belle Mead, NJ EM Inc USA 01.03.1997
Excerpta Medica
Subjects
AIDS-Related Opportunistic Infections - drug therapy
Animals
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Biological and medical sciences
Drug Interactions
Drug Therapy, Combination
Female
HIV Infections - drug therapy
human immunodeficiency virus
Humans
indinavir
Lactation - drug effects
Medical sciences
nelfinavir
Pharmacology. Drug treatments
Pregnancy
protease inhibitors
Protease Inhibitors - adverse effects
Protease Inhibitors - pharmacology
Protease Inhibitors - therapeutic use
ritonavir
saquinavir
human immunodeficiency virus
protease inhibitors
indinavir
nelfinavir
saquinavir
ritonavir
Human
Immunopathology
Monograph
Enzyme
Enzyme inhibitor
AIDS
Review
Immune deficiency
Infection
Peptidases
Chemotherapy
Treatment
Viral disease
Hydrolases
Antiviral
Online AccessGet full text

Cover

More Information
Summary:As one of the largest growing classes of antiretroviral drugs, protease inhibitors are promising agents for the management of patients infected with the human immuno deficiency virus (HIV). We reviewed the literature and compared efficacy, dosing, side effects, and drug-interaction profiles of the protease inhibitors saquinavir, ritonavir, indinavir, and nelfinavir. We addressed the used of these antiprotease agents as monotherapy versus use in combination therapy with other antiretroviral medications, and the potential for HIV to develop resistance to this drug class. We also discussed therapy with dual protease inhibitors and the use of protease inhibitors in pregnant or lactating women and in pediatric patients. Finally, we examined case reports of the addition of protease inhibitors to an antiretroviral regimen that ultimately decreases or reverses opportunistic infections
ISSN:0149-2918
1879-114X
DOI:10.1016/S0149-2918(97)80110-5